Determining associations between human diseases and non-coding RNAs with critical roles in network control

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kagami, Haruna ^a   Akutsu, Tatsuya ^b   Maegawa, Shingo ^b   Hosokawa, Hiroshi ^b   Nacher, Jose C ^a  

^a TOHO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BINDING; RNA BINDING PROTEIN; UNTRANSLATED RNA;

BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM;

GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; RNA, UNTRANSLATED; RNA-BINDING PROTEINS;

EID: 84944350960     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14577     Document Type: Article

References (56)

1. Frith, M. C., Pheasant, M. and Mattick, J. S. The amazing complexity of the human transcriptome. Eur. J. Hum. Genet. 13, 894-897 (2005).
2. Mattick, J. S and Makunin, I. V. Non-coding RNA. Hum Mol Genet. 1, R17-29 (2006).
3. Makeyev, E. V. and Maniatis, T. Multilevel regulation of gene expression by MicroRNAs. Science 319, 1789-1790 (2008).
4. Esquela-Kerscher, A. and Slack, F. J. Oncomirs-microRNAs with a role in cancer. Nature Rev. Cancer 6, 259-269 (2006).
5. Cui, Q., Yu, Z., Pan, Y., Purisima, E. O. and Wang, E. MicroRNAs preferentially target the genes with high transcriptional regulation complexity. Biochem. Biophys. Res. Commun. 352, 733-738 (2007).
6. He, L. et al. A microRNA plycistron as a potential human oncogene. Nature 435, 828-833 (2005).
7. Volinia, S. et al. A microRNA expression signature of human solid tumors define gene targets. Proc. Natl. Acad, Sci. USA. 103, 2257-2261 (2006).
8. Medina, P.P. and Slack, F.J. MicroRNAs and cancer: an overview. Cell Cycle 7, 2485-2492 (2008).
9. Drakaki, A. and Iliopoulos, D. MicroRNA gene networks in oncogenesis. Curr. Genomics 10, 35-41 (2009).
10. Roberts, A. P. E., Lewis, A. P. and Jopling, C. L. The role of microRNAs in viral infection. Progress in molecular biology and translational science 102, 101-139 (2011).
11. Lin, S. and Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nature Reviews Cancer 15, 321-333 (2015).
12. Alvarez-Garcia, I. and Miska, E. A. MicroRNA functions in animal development and human disease. Development 132, 4653-4662 (2005).
13. van Rooij, E. and Olson, E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Invest. 117, 2369-2376 (2007).
14. Poy, M. N., Spranger, M. and Stoffel, M. MicroRNAs and the regulation of glucose and lipid metabolism. Diabetes, Obesity and Metabolism 9, 67-73 (2007).
15. Lu, M. et al. An analysis of human microRNA and disease associations. PLoS One 3(10), e3420 (2008).
16. Van Rooij, E. and Olson, E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nature Reviews Drug Discovery 11, 860-872 (2012).
17. Li, Z. and Rana, T. M. Therapeutic targeting of microRNAs: current status and future challenges. Nature Reviews Drug Discovery 13, 622-638 (2014).
18. Yuan, J. et al. NPInter v2.0: an updated database of ncRNA interactions. Nucleic Acids Res. 42, D104-108 (2014).
19. Wu, T. et al. NPInter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res. 34, D150-D152 (2006).
20. Nacher, J. C. and Akutsu, T. Analysis of critical and redundant nodes in controllingdirected and undirected complex networks using dominating sets. Journal of Complex Networks 2, 394-412 (2014).
21. Liu, Y.-Y., Slotine, J. J. and Barabasi, A.-L. Controllability of complex networks. Nature. 473, 167-173 (2011).
22. Nacher, J. C. and Akutsu, T. Dominating scale-free networks with variable scaling exponent: heterogeneous networks are not difficult to control. New Journal of Physics 14, 073005 (2012).
23. Nacher, J. C and Akutsu, T. Structural controllability of unidirectional bipartite networks. Scientific Reports 3, 1647 (2013).
24. Molnar, F., Sreenivasan, S., Szymanski, B. K. and Korniss, G. Minimum dominating sets in scale-free network ensembles. Scientific Reports 3, 1736 (2013).
25. Vazquez, A. Optimal drug combinations and minimal hitting sets. BMC Systems Biology 3, 81 (2009).
26. Milenkovic, T., Memisevic, V., Bonato, A. and Przulj, N. Dominating biological networks. PLoS One 6(8), e23016 (2011).
27. Wuchty, S. Controllability in protein interaction networks. Proc. Natl. Acad. Sci. 111, 7156-7160 (2014).
28. Jia, T. et al. Emergence of bimodality in controlling complex networks. Nature Communications 4, 2002 (2013).
29. Li, Y. et al. HMDD v2.0: a database for experimentally supported human microRNA and disease associations. Nucl. Acids Res. 42, D1070-4 (2014).
30. Rossi, S. et al. OMiR: Identification of associations between OMIM diseases and microRNAs. Genomics 97, 71-76 (2011).
31. Zhu, J. J., Fu, H. J, Wu, Y. G. and Zheng, X. F. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci. China Life Sci. 56, 876-885 (2013).
32. Fatica, A. and Bozzoni, I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 15, 7-21 (2014).
33. Hangauer, M. J., Vaughn, I. W. and McManus, M. T. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genetics. 9(6), e1003569 (1-13) (2013).
34. Cabili, M. N. et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes and Development 25, 1915-1927 (2011).
35. Liao, Q. et al. Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res. 39(9), 3864-3878 (2011).
36. Cui, Z. et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol. 31(7), 1117-1123 (2012).
37. Meng, Q. et al. ERR-10: a new repressor in transcriptional signaling activation of estrogen receptor-alpha. FEBS Lett. 576(1-2), 190-200 (2004).
38. Rapicavoli, N. A., Poth, E. M. and Blackshaw, S. The long noncoding RNA RNCR2 directs mouse retinal cell specification. BMC Dev. Biol. 10, 49 (2010).
39. Madamanchi, N. R. et al. A noncoding RNA regulates human protease activated receptor-1 gene during embryogenesis. Biochim Biophys Acta. 1576(3), 237-245 (2002).
40. Carramusa, L. et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J. Cell Physiol. 213(2), 511-518 (2007).
41. Colombo, T., Farina, L., Macino, G. and Paci, P. PVT1: A Rising Star among Oncogenic Long Noncoding RNAs. BioMed Research International. vol. 2015, Article ID 304208, 10 pp (2015).
42. Mogilyansky, E. and Rigoutsos, I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death and Differentiation 20, 1603-1614, (2013).
43. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
44. Ota, A. et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Research 64, 3087-3095 (2004).
45. Hebert, S. S. and De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease. Trends in Neurosciences 32, 199-206 (2009).
46. Schonrock, N., Matamales, M., Ittner, L. M. and Goetz, J. MicroRNA networks surrounding APP and amyloid-beta metabolism- Implications for Alzheimers disease. Experimental Neurology 235, 447-454 (2012).
47. Ma, W. J., Cheng, S., Campbell, C, Wright, A. and Furneaux, H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. Journal of Biological Chemistry 271, 8144-8151 (1996).
48. Brennan, C. M. and Steitz, J. A. HuR and mRNA stability. Cellular and Molecular Life Sciences 58, 266-277 (2001).
49. Srikantan, S. and Gorospe, M. HuR function in disease. Frontiers in Bioscience-Landmark 17, 189-205 (2012).
50. Bell, J. L. et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cellular and Molecular Life Sciences 70, 2657-2675 (2013).
51. Spassov, D. S. and Jurecic, R. The PUF family of RNA-binding proteins: Does evolutionarily conserved structure equal conserved function? Iubmb Life 55, 359-366 (2003).
52. Moore, F. L. et al. Human Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with DAZ (Deleted in AZoospermia) and DAZ-Like proteins. Proceedings of the National Academy of Sciences of the United States of America 100, 538-543 (2003).
53. Antonarakis, S. E. and Beckmann, J. S. Mendelian disorders deserve more attention. Nature Reviews Genetics. 7, 277-282 (2006).
54. Barabasi, A.-L., Gulbahce, N. and Loscalzo, J. Network medicine: a network-based approach to human disease. Nature Reviews Genetics 12, 56-68 (2011).
55. Csermely, P., Korcsmaros, T., Kiss, H. J. M., London, G. and Nussinov, R. Structure and dynamics of biological networks: a novel paradigm of drug discovery. A comprehensive review. Pharmacol. Ther. 138, 333-408 (2013).
56. Menche, A. et al. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601-8 (2015).